Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse Events

Key Points

• This analysis aims to evaluate the short-term and long-term safety of brexpiprazole in treating agitation linked to Alzheimer's disease.
• Post hoc analysis of multiple clinical trials
• Examination of adverse events associated with brexpiprazole
• Focus on timing and duration of reported effects
• Identified specific adverse events related to brexpiprazole
• Assessed both short-term and long-term safety profiles
• Provided insights into the timing of adverse events for better patient management